A5047095671- Cancer-related Molecular Pathways
- Acute Myeloid Leukemia Research
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Cancer-related gene regulation
- RNA modifications and cancer
- Click Chemistry and Applications
- Ubiquitin and proteasome pathways
- Cancer Genomics and Diagnostics
Ludwig Cancer Research
2024
University of Oxford
2024
University of St Andrews
2021-2022
C-to-T transitions in CpG dinucleotides are the most prevalent mutations human cancers and genetic diseases. These have been attributed to deamination of 5-methylcytosine (5mC), an epigenetic modification found on CpGs. We recently linked CpG>TpG replication hypothesized that errors introduced by polymerase ε (Pol ε) may represent alternative source mutations. Here we present a new method called error rate sequencing (PER-seq) measure spectrum DNA polymerases isolation. find common...
Acute myeloid leukemia (AML) stem cells are required for the initiation and maintenance of disease. Activation Wnt/β-catenin pathway is survival development AML leukaemia (LSCs) therefore, targeting β-catenin a potential therapeutic strategy. NUC-7738, phosphoramidate transformation 3’-deoxyadenosine (3’-dA) monophosphate, specifically designed to generate active anti-cancer metabolite triphosphate (3’-dATP) intracellularly, bypassing key limitations breakdown, transport, activation....
Background: NUC-7738, a phosphoramidate transformation of 3’deoxyadenosine (3’dA), is specifically designed to generate the active anti-cancer metabolite 3’-deoxyadenosine triphosphate (3’-dATP) directly in cells, bypassing key cancer resistance mechanisms transport, activation and breakdown. NUC-7738 currently Phase I/II clinical study assess safety determine recommended dose patients with advanced solid tumors lymphoma. We have recently shown cell lines potential therapeutic role for acute...
Abstract Background NUC-7738, a phosphoramidate transformation of 3’deoxyadenosine (3’dA), is specifically designed to generate the active anti-cancer metabolite 3’-deoxyadenosine monophosphate (3’-dAMP) directly in cells, bypassing key cancer resistance mechanisms transport, activation and breakdown. NUC-7738 currently Phase I clinical study assess safety determine recommended dose patients with advanced solid tumors lymphoma. Acute myeloid leukemia (AML) cells exhibit impaired...